RAC1 and inflammatory bowel disease: Furthermore, the active 6-TG metabolite 6-thioguanosine 5′-triphosphate was shown to inhibit the small GTPase Rac1 (42), which is believed to be largely responsible for the anti-inflammatory effects of 6-TG in treating inflammatory bowel disease (IBD) (43).